Alumis Inc. (ALMS)
- Sector
- Pharmaceuticals
- Last price
- $6.56
- As of
Kresmion compiles this page from ALMS's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
ALUMIS INC. (ALMS): 4 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-01.
See the full ALMS dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for ALMS on one page. Preview it with sample data, then open it live with a free account.
Preview the ALMS dossierActive signals for ALMS
- mediumEARNINGS_MISS
Q2-2026: Missed consensus by 6.2%, EPS $-0.79 vs $-0.7436 estimate
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +102% to ALMS (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +161% to ALMS (2026Q2)
- highINSTITUTIONAL_EXIT
RENAISSANCE TECHNOLOGIES LLC cut 69% of ALMS (2026Q2)
- highINSTITUTIONAL_SURGE
D. E. Shaw & Co., Inc. added +69% to ALMS (2026Q2)
FREE, NO ACCOUNT
Every signal on ALMS, as it fires
You are seeing 5 of 12 signals recorded on ALMS since 2026-05-26.
The five above landed across 2 days. The other 7 were recorded on 2 other days. 7 of the 12 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in ALMS (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| D. E. Shaw & Co., Inc.CUSIP 022307102 · 2026Q2 | $27.2M | 0.01% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 022307102 · 2026Q2 | $18.6M | 0.01% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 022307102 · 2026Q2 | $10.6M | 0.01% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 022307102 · 2026Q2 | $657K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, ALMS
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
ALMS against its peers
ALMS's operating margin of -1886.9% ranks in the 3rd percentile of 18 Pharmaceuticals sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-06-30.
| Metric | ALMS | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 24.1M USD | 403M USD | 18 | 19 |
| Gross margin | n/a | 59.3% | n/a | 5 |
| Operating margin | -1886.9% | 10.6% | 3 | 18 |
| Net margin | -1011.7% | 0.6% | 3 | 18 |
| Return on equity | -80.8% | -9.3% | 11 | 21 |
| P / E | n/a | 13.7x | n/a | 9 |
| 1 year | 42.3% | 10.8% | 77 | 23 |
Peers (24): ESPR, ANRO, COLL, AMPH, NKTR, ACRS, OMER, PCRX, INVA, PAHC, OCUL, ANIP, NUVB, GPCR, AVIR, TRVI, XERS, BHC, HRMY, LQDA, SUPN, BIOA, FULC, SIGA. Left out: ACB (period gap). Fiscal periods ending between 2025-12-31 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (ALMS: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow ALMS on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to ALMS for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.